161 related articles for article (PubMed ID: 19280712)
1. The tolerogenic peptide hCDR1 downregulates pathogenic cytokines and apoptosis and upregulates immunosuppressive molecules and regulatory T cells in peripheral blood mononuclear cells of lupus patients.
Sthoeger ZM; Sharabi A; Dayan M; Zinger H; Asher I; Sela U; Mozes E
Hum Immunol; 2009 Mar; 70(3):139-45. PubMed ID: 19280712
[TBL] [Abstract][Full Text] [Related]
2. Treatment of lupus patients with a tolerogenic peptide, hCDR1 (Edratide): immunomodulation of gene expression.
Sthoeger ZM; Sharabi A; Molad Y; Asher I; Zinger H; Dayan M; Mozes E
J Autoimmun; 2009 Aug; 33(1):77-82. PubMed ID: 19346102
[TBL] [Abstract][Full Text] [Related]
3. The tolerogenic peptide hCDR1 immunomodulates cytokine and regulatory molecule gene expression in blood mononuclear cells of primary Sjogren's syndrome patients.
Sthoeger Z; Sharabi A; Asher I; Zinger H; Segal R; Shearer G; Elkayam O; Mozes E
Clin Immunol; 2018 Jul; 192():85-91. PubMed ID: 29730433
[TBL] [Abstract][Full Text] [Related]
4. Bcl-xL is required for the development of functional regulatory CD4 cells in lupus-afflicted mice following treatment with a tolerogenic peptide.
Sharabi A; Lapter S; Mozes E
J Autoimmun; 2010 Mar; 34(2):87-95. PubMed ID: 19596183
[TBL] [Abstract][Full Text] [Related]
5. A peptide based on the complementarity-determining region 1 of an autoantibody ameliorates lupus by up-regulating CD4+CD25+ cells and TGF-beta.
Sharabi A; Zinger H; Zborowsky M; Sthoeger ZM; Mozes E
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8810-5. PubMed ID: 16735466
[TBL] [Abstract][Full Text] [Related]
6. The tolerogenic peptide, hCDR1, down-regulates the expression of interferon-α in murine and human systemic lupus erythematosus.
Sthoeger Z; Zinger H; Sharabi A; Asher I; Mozes E
PLoS One; 2013; 8(3):e60394. PubMed ID: 23555966
[TBL] [Abstract][Full Text] [Related]
7. The negative regulators Foxj1 and Foxo3a are up-regulated by a peptide that inhibits systemic lupus erythematosus-associated T cell responses.
Sela U; Dayan M; Hershkoviz R; Cahalon L; Lider O; Mozes E
Eur J Immunol; 2006 Nov; 36(11):2971-80. PubMed ID: 17051618
[TBL] [Abstract][Full Text] [Related]
8. Clinical amelioration of murine lupus by a peptide based on the complementarity determining region-1 of an autoantibody and by cyclophosphamide: similarities and differences in the mechanisms of action.
Sharabi A; Azulai H; Sthoeger ZM; Mozes E
Immunology; 2007 Jun; 121(2):248-57. PubMed ID: 17346282
[TBL] [Abstract][Full Text] [Related]
9. Indoleamine-2,3-dioxygenase in murine and human systemic lupus erythematosus: Down-regulation by the tolerogeneic peptide hCDR1.
Sthoeger Z; Sharabi A; Zinger H; Asher I; Mozes E
Clin Immunol; 2018 Dec; 197():34-39. PubMed ID: 30170030
[TBL] [Abstract][Full Text] [Related]
10. Amelioration of brain pathology and behavioral dysfunction in mice with lupus following treatment with a tolerogenic peptide.
Lapter S; Marom A; Meshorer A; Elmann A; Sharabi A; Vadai E; Neufeld A; Sztainberg Y; Gil S; Getselter D; Chen A; Mozes E
Arthritis Rheum; 2009 Dec; 60(12):3744-54. PubMed ID: 19950283
[TBL] [Abstract][Full Text] [Related]
11. The suppression of murine lupus by a tolerogenic peptide involves foxp3-expressing CD8 cells that are required for the optimal induction and function of foxp3-expressing CD4 cells.
Sharabi A; Mozes E
J Immunol; 2008 Sep; 181(5):3243-51. PubMed ID: 18713995
[TBL] [Abstract][Full Text] [Related]
12. A novel tolerogenic peptide, hCDR1, for the specific treatment of systemic lupus erythematosus.
Mozes E; Sharabi A
Autoimmun Rev; 2010 Nov; 10(1):22-6. PubMed ID: 20659591
[TBL] [Abstract][Full Text] [Related]
13. A new model of induced experimental systemic lupus erythematosus (SLE) in pigs and its amelioration by treatment with a tolerogenic peptide.
Sharabi A; Dayan M; Zinger H; Mozes E
J Clin Immunol; 2010 Jan; 30(1):34-44. PubMed ID: 19756988
[TBL] [Abstract][Full Text] [Related]
14. A tolerogenic peptide down-regulates mature B cells in bone marrow of lupus-afflicted mice by inhibition of interleukin-7, leading to apoptosis.
Ben-David H; Sharabi A; Parameswaran R; Zinger H; Mozes E
Immunology; 2009 Oct; 128(2):245-52. PubMed ID: 19740381
[TBL] [Abstract][Full Text] [Related]
15. The role of apoptosis in the ameliorating effects of a CDR1-based peptide on lupus manifestations in a mouse model.
Sharabi A; Luger D; Ben-David H; Dayan M; Zinger H; Mozes E
J Immunol; 2007 Oct; 179(8):4979-87. PubMed ID: 17911582
[TBL] [Abstract][Full Text] [Related]
16. Identification and characterization of Foxp3(+) gammadelta T cells in mouse and human.
Kang N; Tang L; Li X; Wu D; Li W; Chen X; Cui L; Ba D; He W
Immunol Lett; 2009 Aug; 125(2):105-13. PubMed ID: 19539651
[TBL] [Abstract][Full Text] [Related]
17. Role of Treg cells and TGF-β1 in patients with systemic lupus erythematosus: a possible relation with lupus nephritis.
Xing Q; Su H; Cui J; Wang B
Immunol Invest; 2012; 41(1):15-27. PubMed ID: 21563925
[TBL] [Abstract][Full Text] [Related]
18. CD4(+)CD25 (+) regulatory T cells in human lupus erythematosus.
Kuhn A; Beissert S; Krammer PH
Arch Dermatol Res; 2009 Jan; 301(1):71-81. PubMed ID: 18985367
[TBL] [Abstract][Full Text] [Related]
19. The role of dendritic cells in the mechanism of action of a peptide that ameliorates lupus in murine models.
Sela U; Sharabi A; Dayan M; Hershkoviz R; Mozes E
Immunology; 2009 Sep; 128(1 Suppl):e395-405. PubMed ID: 19040426
[TBL] [Abstract][Full Text] [Related]
20. Mycophenolic acid inhibits SLE-associated cytokine expression and promotes apoptosis of peripheral blood mononuclear cells from patients with systemic lupus erythematosus.
Su DL; Wang HJ; Ji XH; Li YY; Xuan HB; Heng C; Li YF
Acta Pharmacol Sin; 2006 Aug; 27(8):1051-7. PubMed ID: 16867258
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
